{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:24Z","timestamp":1792166184825,"version":"4.4.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) caused by an autoantibody-mediated deficiency of ADAMTS13 and atypical hemolytic syndrome (aHUS) caused by alternative complement dysregulation are the most common primary thrombotic microangiopathies (TMAs). The evaluation of a patient with TMA is a medical emergency since it is critical to quickly distinguish iTTP and aHUS from other causes of TMA. Untreated iTTP is rapidly fatal, and delays in initiating complement inhibition in aHUS increase the risk of irreversible renal failure. An ADAMTS13 activity level of less than 10% is diagnostic of iTTP in the appropriate clinical setting. In settings where rapid-turnaround ADAMTS13 testing is not available, clinical features and clinical prediction tools are useful to identify patients who should receive emergent plasma exchange. We present an evidence-based approach to the initial (first 24 hours) diagnosis and management of iTTP and review the clinical and laboratory features that can be used to identify patients with aHUS who will benefit from early C5 blockade. We also discuss the potential use of complement blockade to improve outcomes in selected patients with secondary TMA.<\/jats:p>","DOI":"10.1182\/hematology.2023000501","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:15:12Z","timestamp":1702048512000},"page":"745-753","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Medical consult: aHUS, TTP? How to distinguish and what to do"],"prefix":"10.1182","volume":"2023","author":[{"given":"Charlotte M.","family":"Story","sequence":"first","affiliation":[{"name":"1 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria F","family":"Gerber","sequence":"additional","affiliation":[{"name":"2 Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"2 Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"2","key":"2023120815090392700_hem2023000501C1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1751-553X.2011.01380.x","article-title":"ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes","volume":"34","author":"Zini","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"9","key":"2023120815090392700_hem2023000501C2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2023120815090392700_hem2023000501C3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023120815090392700_hem2023000501C4","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"issue":"1","key":"2023120815090392700_hem2023000501C5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"10","key":"2023120815090392700_hem2023000501C6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2023120815090392700_hem2023000501C7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"12","key":"2023120815090392700_hem2023000501C8","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2023120815090392700_hem2023000501C9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2023120815090392700_hem2023000501C10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"issue":"4","key":"2023120815090392700_hem2023000501C11","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"2023120815090392700_hem2023000501C12","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023120815090392700_hem2023000501C13","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion"},{"issue":"1","key":"2023120815090392700_hem2023000501C14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/trf.16188","article-title":"Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals","volume":"61","author":"Liu","year":"2021","journal-title":"Transfusion"},{"issue":"8","key":"2023120815090392700_hem2023000501C15","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ajh.26241","article-title":"Laboratory testing for ADAMTS13: utility for TTP diagnosis\/exclusion and beyond","volume":"96","author":"Favaloro","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2023120815090392700_hem2023000501C16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.13654","article-title":"The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry","volume":"171","author":"Hassan","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2023120815090392700_hem2023000501C17","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2023120815090392700_hem2023000501C18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SHK.0000000000000341","article-title":"ADAMTS-13 in critically ill patients with septic syndromes and noninfectious systemic inflammatory response syndrome","volume":"43","author":"Aibar","year":"2015","journal-title":"Shock"},{"issue":"9","key":"2023120815090392700_hem2023000501C19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","article-title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","volume":"132","author":"Masias","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2023120815090392700_hem2023000501C20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"},{"issue":"9","key":"2023120815090392700_hem2023000501C21","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2023120815090392700_hem2023000501C22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2023120815090392700_hem2023000501C23","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14815","article-title":"A multi-center evaluation of TECHNOSCREEN\u00ae ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13","volume":"18","author":"Moore","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2023120815090392700_hem2023000501C24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2023120815090392700_hem2023000501C25","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity","volume":"119","author":"Valsecchi","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023120815090392700_hem2023000501C26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2023120815090392700_hem2023000501C27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2023120815090392700_hem2023000501C28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission","volume":"181","author":"Volokhina","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"24","key":"2023120815090392700_hem2023000501C29","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2023120815090392700_hem2023000501C30","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023120815090392700_hem2023000501C31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2023120815090392700_hem2023000501C32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2022015583","article-title":"How I treat thrombotic microangiopathy in the era of rapid genomics","volume":"141","author":"Doreille","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2023120815090392700_hem2023000501C33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"2023120815090392700_hem2023000501C34","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023120815090392700_hem2023000501C35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2023120815090392700_hem2023000501C36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023120815090392700_hem2023000501C37","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(20)30406-3","article-title":"NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura","volume":"8","author":"Hughes","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023120815090392700_hem2023000501C38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2020009250","article-title":"Counting the cost of caplacizumab","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023120815090392700_hem2023000501C39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2023120815090392700_hem2023000501C40","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2023120815090392700_hem2023000501C41","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"2023120815090392700_hem2023000501C42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40273-019-00862-w","article-title":"Economic impact of early-in-hospital diagnosis and initiation of eculizumab in atypical haemolytic uraemic syndrome","volume":"38","author":"Ryan","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"2023120815090392700_hem2023000501C43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2023120815090392700_hem2023000501C44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/745\/2175981\/745story.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/745\/2175981\/745story.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:15:31Z","timestamp":1702048531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/745\/506485\/Medical-consult-aHUS-TTP-How-to-distinguish-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000501","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}